A new covid booster is here. Will those at greatest risk get it?

The Centers for Disease Control and Prevention recommends new covid-19 booster vaccines for all — but many who need them most won’t get them. About 75% of people in the United States appear to have skipped last year’s bivalent booster, and nothing suggests uptake will be better this time around.

Zelis Unveils New In-Network Pricing Solution for Streamlined Claim Processing

What You Should Know: Zelis, a leader in healthcare technology solutions, has announced its newest weapon in the fight against opaque claim pricing: In-Network Pricing

March 27, 2024

Semaglutide May Be Linked to Condition That Causes Blindness

Use of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy) may be linked with an increased risk of the second most common form of optic neuropathy,

July 4, 2024

Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug – Pharmaceutical Technology

Sanofi gains exclusive commercialisation rights for losmapimod outside of the US. Credit: HJBC via Shutterstock. Fulcrum Therapeutics has signed a $1bn exclusive licence deal with

May 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.